| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| The Johns Hopkins Ovarian Cancer Center of Excellence acknowledges and thanks Aventis, Genzyme, GlaxoSmithKline, Oncotech, Ortho Biotech, and The Pam McDonald Fund for their support of this website through provision of unrestricted educational grants. |
|
 |
|
 |
 |
 |
 |
Heated Intraperitoneal Chemotherapy |
|
 |
|
 |
|
IP chemo as first line treatment |
|
|
|
 |
|
Perineal talc use and ovarian cancer |
|
|
|
 |
|
Patient Profile - Janice Paulshock & Rebecca Coder |
|
|
|
|
|
 |
 |
 |
LATEST OVARIAN CANCER NEWS
|
Blood test provides early detection of ovarian cancer |
|
Reuters Health
Last Modified: February 15, 2008
|
Last Updated: 2008-02-15 15:31:39 -0400 (Reuters Health)
NEW YORK (Reuters Health) - Researchers have developed what they believe is the first blood biomarker test that accurately detects ovarian cancer at an early stage.
"The ability to recognize almost 100% of new tumors will have a major impact on the high death rates of this cancer," senior author Dr. Gil Mor, from Yale University School of Medicine in New Haven, Connecticut, said in a statement. "We hope this test will become the standard of care for women having routine examinations."
In a 2005 study, Dr. Mor's team first described a biomarker panel that can detect stage I and II ovarian cancer. In the present phase II trial, the researchers expanded the panel from four proteins to six and used a multiplex, bead-based immunoassay system to measure protein levels in 362 healthy controls and 156 newly diagnosed ovarian cancer patients.
The six proteins included in the test were leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125, according to the report in the February 15th issue of Clinical Cancer Research.
Alone, none of the biomarkers could distinguish the cancer patients from the healthy controls, the authors note. When all six biomarkers were measured, however, the test was 95.3% sensitive and 99.4% specific in detecting ovarian cancer.
A phase III evaluation of the biomarker assay is currently underway.
Clin Cancer Res 2008;14:1065-1072.
|
|
GnRH agonist reduces chemotherapy-induced ovarian failure |
|
Megan Rauscher
Reuters Health
Last Modified: February 20, 2008
|
Last Updated: 2008-02-20 16:04:22 -0400 (Reuters Health)
NEW YORK (Reuters Health) - In a study of women of reproductive age undergoing chemotherapy for Hodgkin's lymphoma, cotreatment with a gonadotrophin-releasing hormone (GnRH) agonist significantly reduced ovarian damage.
Dr. Zeev Blumenfeld who led the study told Reuters Health: "The important and practical message from the study is that women in the reproductive age (14 to 40 years) should be offered the option of suppression of the menstrual cycle and temporary creation of a pre-pubertal hormonal milieu."
Dr. Blumenfeld and colleagues from Rambam Health Care Campus, Technion-Israel Institute of Technology in Haifa, Israel, compared the ovarian function of a group of women with Hodgkin's lymphoma who received a monthly injection of a GnRH agonist, administered before the start of chemotherapy until its end, up to a maximum of 6 months, with that of a group of women who were treated with similar chemotherapy for Hodgkin's lymphoma but without the GnRH agonist (the controls).
According to a report in the January issue of Fertility and Sterility, only 2 of the 65 patients available for evaluation in the GnRH agonist group developed premature ovarian failure (3.1%) and the remaining 63 (96.9%) resumed cyclic ovarian function within 2 years and/or conceived.
In contrast, 17 out of 46 (37%) control patients who did not receive GnRH agonist therapy developed premature ovarian failure. Of the 46 control patients, 20 were historical controls treated between 1980 and 1990 and 26 were concurrently treated with similar chemotherapy. There were no significant differences between the two groups in the cumulative doses of the various alkylating agents used.
"The risk of premature menopause with the monthly GnRH agonist injections," Dr. Blumenfeld noted, "is less than 8% as compared to 40% to 50% without it. In high-risk cases, this treatment should be considered in addition to IVF and cryopreservation of embryos, ova, and/or ovarian tissue."
"The added value of the GnRH agonist injections is that it will prevent the severe menstrual bleeding associated with decreased platelet counts (thrombocytopenia) generated by the chemotherapy," Dr. Blumenfeld added.
Fertil Steril 2008;89:166-173.
|
Johns Hopkins/Franklin Square patients: Sign up for the Survivor Network
Our team of experts brings together the cutting edge technological resources, expertise, and research of the Johns Hopkins Medical Institutions and Johns Hopkins Kimmel Cancer Center to offer a proactive and aggressive approach to the treatment of women with ovarian cancer. We focus on a comprehensive and holistic approach to deliver the best possible care to our patients.
Surgical Expertise - Dr. Robert Bristow, director of the Johns Hopkins Ovarian Cancer Center of Excellence, and the team of Johns Hopkins Hospital gynecologic cancer surgeons have expertise in a full range of surgical options including staging, debulking, and primary and secondary surgeries. Patients benefit by receiving the most comprehensive treatment plan from the time they are diagnosed. Learn more about how ovarian cancer care "is one step closer to home."
Contemporary Treatment and Advanced Technology - Our team of medical experts offers access to the most advanced diagnostic tools including combined PET/CT for surveillance and early detection of recurrent disease, and leading medical oncologists, access to clinical trials, contemporary chemotherapy including intra-peritoneal (IP) treatment for appropriate patients, as well as expert gynecologic pathology reviews.
Holistic Care and Comprehensive Therapies - At our Center, we treat the entire patient, not just her disease, in a holistic approach to care. Our center offers a full spectrum of services such as patient and family counseling, nutrition and dietary counseling, integrative and rehabilitative physical medicine, complementary medicine, and sexual medicine.
Leading Researchers - Teams of scientists specializing in ovarian cancer epidemiology, molecular biology, imaging, surgical treatment, chemotherapy, and developmental therapeutics bring world-renowned expertise to pave the way for advances in ovarian cancer screening, diagnosis and treatment.
Community - We provide access to the Johns Hopkins community of patients and family support, as well as outreach and educational programs emphasizing education and awareness about ovarian cancer.
|
